• Explore /
  • Poster
  • / NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.

NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.

Abstract Poster

Authors

Dean Bajorin

Dean F. Bajorin

Memorial Sloan-Kettering Cancer Center, New York, NY

Dean F. Bajorin , Padmanee Sharma , Leonard G. Gomella , Elizabeth R. Plimack , Peter H. O'Donnell , Jean H. Hoffman-Censits , Thomas W. Flaig , David I. Quinn , Robert Brownell Sims , Michael Locker , Nadeem A. Sheikh , Todd DeVries , Seth P. Lerner

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancers, and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Urothelial Carcinoma

Clinical Trial Registration Number

NCT01353222

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 296^)

DOI

10.1200/jco.2014.32.4_suppl.296

Abstract #

296^

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Dean F. Bajorin

First Author: Dean F. Bajorin

First Author: Dean F. Bajorin

First Author: Michael F. Press